Form 4: Provectus CEO Converts Note to Preferred Stock

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a change in beneficial ownership.
• An 8% unsecured convertible promissory note, with a principal amount of $75,000, was converted into 28,320 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred on August 29, 2025, at a price of $2.862 per share of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.
• Following this transaction, Edward Pershing beneficially owns 2,380,687 shares of Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The conversion of debt to equity by an insider can be seen as a sign of confidence, but it also introduces potential future dilution for common shareholders. The transaction itself is a pre-planned event.

Positives

• An insider, the CEO, is increasing their equity exposure through the conversion of a debt instrument, potentially signaling confidence in the company's long-term prospects.
• The conversion of the promissory note reduces the company's outstanding debt, albeit by converting it into a different form of equity.

Negatives

• The conversion of preferred stock into common stock in the future will result in dilution for existing common shareholders.
• The original promissory note was unsecured, indicating a higher risk profile for the debt holder.

Risks

• Future conversion of the Series D-1 Convertible Preferred Stock into common stock will dilute the ownership percentage of existing common shareholders.
• The value of the underlying common stock upon conversion is subject to market fluctuations, which could impact the ultimate value realized by the reporting person and existing shareholders.

Future Outlook

The Series D-1 Convertible Preferred Stock acquired by Edward Pershing will automatically convert into Common Stock on June 20, 2026, unless an earlier voluntary conversion occurs in accordance with its terms.

Industry Context

This type of convertible debt financing and subsequent conversion by an insider is a common mechanism in the biotechnology and pharmaceutical industry for capital raising and executive compensation, aligning management interests with long-term company performance.

Comparison to Industry Standards

• Convertible notes are a standard financing tool in the biotech sector, often used by companies like Provectus Biopharmaceuticals to raise capital while deferring immediate equity dilution.
• Insider conversions of such instruments are routine disclosures, similar to those seen in other development-stage biopharmaceutical companies where management often participates in financing rounds.

Related Party Transactions

• The transaction involves Edward Pershing, the CEO and a Director of Provectus Biopharmaceuticals, Inc., making it a related party transaction.

Stakeholder Impact

• Shareholders: Face potential future dilution of their common stock holdings when the Series D-1 Preferred Stock converts into common stock.
• Creditors: The conversion of the promissory note reduces the company's outstanding debt obligations.

Next Steps

• Automatic conversion of the Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026, or earlier voluntary conversion.

Key Dates

Recommendation

This Form 4 filing details a pre-planned conversion of a convertible note by an insider, which is a routine disclosure. It does not contain new financial performance data, strategic shifts, or unexpected events that would warrant a change in investment stance based solely on this document. The potential for future dilution from the preferred stock conversion is noted but is a known characteristic of such instruments.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Form 4, Insider Transaction, Convertible Note, Preferred Stock, Common Stock, Equity Conversion, CEO, Director, Rule 10b5-1(c)